SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALO', Girolamo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.483
AS - Asia 15.441
EU - Europa 8.331
SA - Sud America 2.322
AF - Africa 341
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 15
Totale 58.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.931
SG - Singapore 5.963
CN - Cina 3.874
DE - Germania 1.807
BR - Brasile 1.785
VN - Vietnam 1.776
UA - Ucraina 1.469
IT - Italia 1.210
HK - Hong Kong 1.206
GB - Regno Unito 958
TR - Turchia 956
FI - Finlandia 767
FR - Francia 528
RU - Federazione Russa 415
SE - Svezia 379
JP - Giappone 353
IN - India 308
CA - Canada 264
PL - Polonia 213
MX - Messico 212
AR - Argentina 192
BD - Bangladesh 191
ID - Indonesia 176
IQ - Iraq 122
ZA - Sudafrica 121
NL - Olanda 120
BE - Belgio 90
EC - Ecuador 88
PK - Pakistan 82
ES - Italia 73
CO - Colombia 63
LT - Lituania 57
MA - Marocco 57
SA - Arabia Saudita 53
IE - Irlanda 52
VE - Venezuela 51
PH - Filippine 46
UZ - Uzbekistan 46
CL - Cile 42
MY - Malesia 42
CZ - Repubblica Ceca 38
PY - Paraguay 37
TN - Tunisia 37
AT - Austria 36
AE - Emirati Arabi Uniti 32
NP - Nepal 28
EG - Egitto 26
KE - Kenya 25
JO - Giordania 23
UY - Uruguay 23
PE - Perù 21
AZ - Azerbaigian 20
IR - Iran 20
AU - Australia 18
DZ - Algeria 18
AL - Albania 16
KR - Corea 16
CH - Svizzera 15
IL - Israele 15
BO - Bolivia 13
DO - Repubblica Dominicana 12
TH - Thailandia 12
LB - Libano 11
BG - Bulgaria 10
JM - Giamaica 10
RO - Romania 10
SN - Senegal 10
ET - Etiopia 9
NZ - Nuova Zelanda 9
PA - Panama 9
BH - Bahrain 8
GR - Grecia 8
HN - Honduras 8
KZ - Kazakistan 7
NG - Nigeria 7
NI - Nicaragua 7
RS - Serbia 7
TW - Taiwan 7
A2 - ???statistics.table.value.countryCode.A2??? 6
CY - Cipro 6
DK - Danimarca 6
GY - Guiana 6
SV - El Salvador 6
TT - Trinidad e Tobago 6
CR - Costa Rica 5
EU - Europa 5
HR - Croazia 5
LV - Lettonia 5
MD - Moldavia 5
NO - Norvegia 5
OM - Oman 5
PS - Palestinian Territory 5
PT - Portogallo 5
AM - Armenia 4
KG - Kirghizistan 4
KH - Cambogia 4
LK - Sri Lanka 4
LU - Lussemburgo 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
Totale 58.884
Salva come PNG Salva come JPEG
Città #
Singapore 3.790
Ashburn 3.656
Fairfield 3.307
Woodbridge 2.890
Houston 1.994
San Jose 1.751
Jacksonville 1.597
Ann Arbor 1.518
Chandler 1.392
Seattle 1.358
Beijing 1.189
Wilmington 1.182
Hong Kong 1.174
Santa Clara 1.169
Cambridge 1.156
Dallas 1.116
Munich 617
Ho Chi Minh City 579
Izmir 548
Nanjing 457
Los Angeles 450
New York 413
Hanoi 370
Princeton 355
Tokyo 339
Ferrara 327
Helsinki 318
Lauterbourg 308
San Diego 288
Boardman 264
Milan 230
Shanghai 211
São Paulo 200
Warsaw 191
London 140
Nanchang 139
Council Bluffs 131
Shenyang 129
Turku 128
Dearborn 127
Mexico City 119
Orem 116
Falkenstein 109
Hefei 103
Tianjin 103
Frankfurt am Main 100
Jakarta 99
Da Nang 94
The Dalles 93
Falls Church 92
Brooklyn 87
Brussels 84
Montreal 83
Hebei 81
San Mateo 81
Chicago 78
Moscow 78
Norwalk 78
Atlanta 76
Jiaxing 75
Bremen 74
Buffalo 74
Johannesburg 74
Denver 70
Changsha 69
Chennai 67
Toronto 66
Mountain View 64
Redwood City 64
Rio de Janeiro 64
Haiphong 62
Jinan 59
San Francisco 55
Stockholm 55
Guangzhou 53
Phoenix 51
Dublin 50
Bologna 49
Addison 48
Auburn Hills 48
Manchester 48
Washington 48
Boston 47
Dhaka 46
Amsterdam 45
Dong Ket 45
Baghdad 44
Kunming 44
Zhengzhou 44
Philadelphia 43
Mumbai 42
Poplar 42
Tashkent 42
Belo Horizonte 37
Ankara 36
Hải Dương 34
Lahore 33
Columbus 31
Biên Hòa 30
Guayaquil 30
Totale 41.354
Salva come PNG Salva come JPEG
Nome #
1,4-Dioxolane-triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands 992
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 392
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 374
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 336
Chimeric G proteins in fluorimetric calcium assays: Experience with opioid receptors 331
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8 ,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies 309
A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism 291
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 287
A new selective antagonist of the nociceptin receptor 269
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 269
Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations 266
In vitro and in vivo pharmaco-dynamic study of the novel fentanyl derivatives: Acrylfentanyl, Ocfentanyl and Furanylfentanyl 264
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 260
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 259
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 253
A new ligand for the urotensin II receptor 252
Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor 251
Kinin B-1 and B-2 receptors in pig vessels: characterization of two monoreceptor systems 245
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 243
The effect of guanethidine and local anaesthetics on the electrically stimulated mouse vas deferens 240
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 240
Actual concept of "probiotics": is it more functional to science or business? 239
Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2 239
Structure-and conformation-Activity studies of nociceptin/orphanin FQ receptor dimeric ligands 238
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 236
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 235
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. 235
Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5 235
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 235
A simple method for electrical field stimulation of cultured granule cells 234
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 232
[Nphe(1)]N/OFQ-(1-13)-NH2 is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K+ channel activation in rat periaqueductal gray slices 231
Nociceptin/orphanin FQ receptor knockout rats: In vitro and in vivo studies 229
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 229
Structural Bacterial Molecules as Potential Candidates for an Evolution of the Classical Concept of Probiotics 228
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test 228
Effects of vasoactive agents in healthy and diseased human saphenous veins 227
[Nphe(1)]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon 226
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 225
Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120 224
A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials 224
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic- versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands 223
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 223
Characterisation of the novel mixed Mu-NOP peptide ligand dermorphin-N/OFQ (DeNo) 223
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 222
Modulation of the NOP receptor signaling affects resilience to acute stress 220
Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity 219
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 218
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 218
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 217
[Nphe(1),Arg(14),Lys(15)]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray 217
Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor 217
Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation 217
Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt(1)]N/OFQ(1-13) 217
[Nphe(1)]nociceptin-(1-13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum 214
Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone 214
Pharmacological characterization of tachykinin tetrabranched derivatives 214
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 213
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 212
[Nphe(1)]-Nociceptin (1-13)-NH2, a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats 211
Emergency admissions of opioid drug-abusers for overdose. A chronobiological study of enhanced risk 211
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 211
Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test 211
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 210
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 210
Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration 210
B1 and B2 kinin receptors in various species 209
In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. 209
In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403 209
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 208
Pharmacological characterisation of novel kinin B2 receptor ligands 208
Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity 208
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems 208
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 206
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 206
null 205
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 205
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 204
In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant 204
Sudden death from pulmonary thromboembolism: chronobiological aspects 202
Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands 202
Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction 202
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex 201
Pharmacological profile of nociceptin/orphanin FQ receptors interacting with G-proteins and β-arrestins 2 201
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice 201
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 201
Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505). 200
In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations 200
Neuropeptide S receptor ligands: a patent review (2005-2016) 199
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 198
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 198
Pharmacological characterization of nociceptin receptor: an in vitro study 198
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 197
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 196
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 196
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 196
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 195
Structure-activity study at positions 3 and 4 of human neuropeptide S. 194
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus 194
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 193
Totale 23.497
Salva come PNG Salva come JPEG
Categoria #
all - tutte 257.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.604
Totale 261.604
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021855 0 0 0 0 0 0 0 0 0 0 577 278
2021/20223.644 144 369 312 217 203 190 217 236 156 302 313 985
2022/20233.455 379 160 114 414 572 485 177 315 470 21 196 152
2023/20241.783 196 229 88 50 99 310 74 142 35 30 53 477
2024/20257.710 184 203 632 256 875 769 271 496 1.226 795 1.075 928
2025/202621.032 2.223 1.107 2.409 2.779 3.039 1.412 2.592 1.114 1.963 2.327 67 0
Totale 59.463